Arrowstreet Capital’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $77.9M | Buy |
1,383,004
+2,902
| +0.2% | +$189K | 0.04% | 370 |
|
|
2025
Q4 | $111M | Buy |
1,380,102
+1,254,035
| +995% | +$84.3M | 0.06% | 279 |
|
|
2025
Q3 | $6.14M | Buy |
+126,067
| New | +$7.8M | ﹤0.01% | 1109 |
|
|
2024
Q3 | – | Sell |
-110,110
| Closed | -$9.11M | – | 1784 |
|
|
2024
Q2 | $9.11M | Sell |
110,110
-57,387
| -34% | -$5.05M | 0.01% | 662 |
|
|
2024
Q1 | $14.3M | Buy |
167,497
+9,480
| +6% | +$744K | 0.01% | 584 |
|
|
2023
Q4 | $13.5M | Sell |
158,017
-77,187
| -33% | -$6.67M | 0.01% | 492 |
|
|
2023
Q3 | $21.1M | Sell |
235,204
-435,981
| -65% | -$38.9M | 0.03% | 381 |
|
|
2023
Q2 | $57.1M | Buy |
671,185
+10,137
| +2% | +$857K | 0.07% | 225 |
|
|
2023
Q1 | $54.7M | Buy |
661,048
+33,730
| +5% | +$2.73M | 0.07% | 257 |
|
|
2022
Q4 | $49.3M | Buy |
627,318
+454,459
| +263% | +$36.5M | 0.07% | 239 |
|
|
2022
Q3 | $12.8M | Buy |
172,859
+139,181
| +413% | +$9.99M | 0.02% | 469 |
|
|
2022
Q2 | $2.19M | Buy |
+33,678
| New | +$1.99M | ﹤0.01% | 757 |
|
|
2021
Q2 | – | Sell |
-39,300
| Closed | -$4.36M | – | 2019 |
|
|
2021
Q1 | $4.36M | Buy |
39,300
+36,972
| +1,588% | +$4.58M | 0.01% | 1235 |
|
|
2020
Q4 | $276K | Sell |
2,328
-161,874
| -99% | -$17.4M | ﹤0.01% | 2136 |
|
|
2020
Q3 | $14.3M | Sell |
164,202
-42,731
| -21% | -$3.73M | 0.02% | 695 |
|
|
2020
Q2 | $18.5M | Buy |
+206,933
| New | +$20.9M | 0.03% | 529 |
|
|
2019
Q3 | – | Sell |
-17,873
| Closed | -$2.15M | – | 1613 |
|
|
2019
Q2 | $2.15M | Sell |
17,873
-6,727
| -27% | -$662K | ﹤0.01% | 887 |
|
|
2019
Q1 | $2.15M | Buy |
+24,600
| New | +$2.24M | 0.01% | 1084 |
|
|
2018
Q4 | – | Sell |
-187,848
| Closed | -$21.5M | – | 1394 |
|
|
2018
Q3 | $21.5M | Sell |
187,848
-251,434
| -57% | -$26M | 0.05% | 277 |
|
|
2018
Q2 | $39.4M | Buy |
439,282
+355,412
| +424% | +$30M | 0.1% | 200 |
|
|
2018
Q1 | $6.14M | Buy |
+83,870
| New | +$5.75M | 0.01% | 536 |
|
|
2017
Q4 | – | Sell |
-154,861
| Closed | -$6.95M | – | 1306 |
|
|
2017
Q3 | $6.95M | Buy |
154,861
+5
| +0% | +$208 | 0.02% | 435 |
|
|
2017
Q2 | $6.12M | Buy |
+154,856
| New | +$6.36M | 0.02% | 436 |
|
|
2016
Q2 | – | Sell |
-10,800
| Closed | -$378K | – | 1401 |
|
|
2016
Q1 | $378K | Sell |
10,800
-114,553
| -91% | -$3.7M | ﹤0.01% | 1172 |
|
|
2015
Q4 | $4.04M | Buy |
125,353
+32,053
| +34% | +$1.04M | 0.02% | 614 |
|
|
2015
Q3 | $3.02M | Buy |
93,300
+85,000
| +1,024% | +$3.2M | 0.01% | 659 |
|
|
2015
Q2 | $343K | Buy |
+8,300
| New | +$350K | ﹤0.01% | 1037 |
|
|
2014
Q4 | – | Sell |
-20,308
| Closed | -$709K | – | 1268 |
|
|
2014
Q3 | $709K | Buy |
+20,308
| New | +$725K | ﹤0.01% | 780 |
|
|
2014
Q2 | – | Sell |
-111,544
| Closed | -$3.63M | – | 1052 |
|
|
2014
Q1 | $3.63M | Buy |
+111,544
| New | +$4.26M | 0.02% | 509 |
|
Other funds holding HAE
VPM
VCM
RRAM
Arrowstreet Capital's HAE Position: Q1 2026 in Review
Arrowstreet Capital increased its Haemonetics (HAE) stake by 0.21% in Q1 2026, buying an estimated $189K and bringing the position to 1,383,004 shares worth $77.9M. The position accounts for 0.04% of the portfolio, ranked #370.
Arrowstreet Capital first reported a position in HAE in Q1 2014 and has held it in 29 quarters since. The position peaked at $111M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Arrowstreet Capital held 1,383,004 shares of Haemonetics worth $77.9M as of Q1 2026.
- Arrowstreet Capital bought 2,902 Haemonetics shares in Q1 2026, an estimated $189K.
- Haemonetics made up 0.04% of Arrowstreet Capital's portfolio in Q1 2026, its #370 holding.
- Arrowstreet Capital first reported a position in Haemonetics in Q1 2014 and has held it in 29 quarters since.
- Arrowstreet Capital's Haemonetics position peaked at $111M in Q4 2025.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.